New Jersey 2022-2023 Regular Session

New Jersey Assembly Bill A3725

Introduced
5/2/22  

Caption

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

Impact

If enacted, A3725 would amend state laws under the consumer fraud act, introducing punitive measures for violations. These penalties include fines – up to $10,000 for first offenses and $20,000 for subsequent offenses – and additional enforcement mechanisms such as cease and desist orders issued by the Attorney General. This transition reflects a stronger regulatory approach to marketing practices, especially those targeting young individuals.

Summary

Assembly Bill A3725 aims to enhance consumer protection by prohibiting the sale of certain products that use advertisements suggesting a connection to controlled dangerous substances or their analogs. Specifically, the bill forbids the sale of any food, beverage, or products intended to be ingested or inhaled if they are marketed with such advertising. This broader initiative seeks to curtail the promotion of unhealthy or legally questionable products to minors and restricts their access to age-inappropriate merchandise.

Contention

Notable points of contention around A3725 may arise from its implications for marketing practices within the food and beverage industry. Critics could argue that the bill imposes unnecessary limitations on businesses and restricts their ability to market products creatively. Furthermore, concerns may be raised about the bill's scope and how broadly it interprets the idea of advertisements linked to controlled substances, which could lead to impactful changes in how products are labeled and marketed within the state.

Companion Bills

NJ S2336

Same As Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

Previously Filed As

NJ S2336

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ S2741

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ A366

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ S166

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ A784

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ A2174

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ A714

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ HB3567

Controlled dangerous substances; adding to list of Schedule I controlled substances; revocation or suspension of registrations; written orders; repealers; emergency.

NJ A5488

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances; requires reporting of xylazine prescriptions.

NJ AB3029

Controlled substances.

Similar Bills

CA SB921

Political Reform Act of 1974: digital political advertisements.

CA AB868

Political Reform Act of 1974: digital political advertisements.

CA AB794

Cannabis: advertising and marketing restrictions.

CA AB2716

Cannabis: advertisements: highways.

CA AB1175

Outdoor advertising displays: redevelopment agency project areas.

CA AB2546

Commercial email advertisements.

CA AB1982

Outdoor advertising displays: exemptions: City of Artesia.

CA SB405

Outdoor advertising displays: exemptions: City of Artesia.